teclistamab,talquetamab,daratumumab
genmab,janssen
['redirectt-1', 'teclistamab']
the presentation everyone was waiting for: presents the results of the redirectt-1 study combining teclistamab + telquetamab simultaneously targeting bcma and gprc5d. 96.3% overall response rate, and 86.7% in extramedullary soft tissue plasmacytomas! #eha2023 
Myeloma Canada is a registered non-profit organization created by, and for, people living with myeloma. We have been Making Myeloma Matter since 2005.